What are the commercial prospects for the pharmacological treatment of acute coronary syndrome? Our new report shows you its revenue potential from 2011 to 2021. We predict and explain the commercial opportunities in that industry and market.

Our report gives you revenue forecasts to 2021 for treating acute coronary syndrome (ACS). You will find market predictions at total world, submarket, product and national levels. We aim to save you time and aid your decisions through our research, analysis and discussions.

Our study covers ACS treatments, including those for unstable angina (UA) and acute myocardial infarction (AMI). You will see commercial prospects for platelet aggregation inhibitors, anticoagulant treatments, fibrinolytic agents and their subgroups to 2021. 

You will see how drugs like Plavix, Effient/Efient, ReoPro, Integrilin, Aspirin Cardio, Lovenox, Angiomax/Angiox, Arixtra and Metalyse/TNKase will perform to 2021. Our report provides many revenue forecasts and discussions, giving answers you need. 

In particular, we discuss the R&D pipeline. There are opportunities for original and generic drugs for treating acute coronary syndrome from 2011 onwards. 

We help you to assess the ACS treatment industry and market's strengths, weaknesses, trends and revenue opportunities to 2021. You will see what the future holds. 

Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.

Industry and market analysis to help your work - so you won't be left behind

Our report gives you revenue forecasts, growth rates, market shares, a SWOT/STEP review, an R&D review and opinions from our survey. We include 78 tables and charts and a research interview (shown in the accompanying lists).

Acute Coronary Syndrome (ACS) Drug Market Prospects 2011-2021 shows you revenue trends, opportunities and challenges

Our report gives you the following advantages:
• You will receive hard data for the acute coronary syndrome treatments industry and market - especially our revenue forecasts to 2021
• You will discover revenue predictions to 2021 for the overall ACS market and its components, seeing where the highest revenue growth will occur
• You will see the revenue prospects to 2021 for 12 leading drugs, with discussions of market potential and competition
• You will find ACS revenue predictions to 2021 for leading national markets (US, Japan, UK, Germany, France, Spain, Italy, China and India)
• You will learn how the ACS treatment industry will change from 2011 to 2021
• You will review the technologies in development, assessing potential among the R&D product candidates for ACS
• You will investigate competition and opportunities influencing the industry and market from 2011 onwards
• You will see what will stimulate and restrain the industry and market from 2011
• You will investigate commercial requirements - with therapeutic needs and sales opportunities discussed
• You will analyse opportunities and challenges for established companies and those seeking to enter the ACS market
• You will view opinions from our survey.

That mix of quantitative and qualitative market analysis sets our report apart. Our analysis helps you to stay ahead in commercial knowledge for cardiovascular drugs. 

Order our report now to gain industry and market information you need 

Our report can benefit everybody interested in the industry and market for treating acute coronary syndrome. We give predictions and answers you need. Don't miss out - please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
 

Table Of Contents

Table of Contents

1. Executive Summary
1.1 Acute Coronary Syndrome (ACS) Treatment Market Review
1.2 Aims, Scope and Format of the Report
1.2.1 Scope of the Report
1.2.2 Chapter Outlines
1.3 Research and Analysis Methods

2. Cardiovascular Diseases (CVD): Overview
2.1 Financial and Social Costs 
2.2 Coronary Artery Disease (CAD)
2.3 Acute Coronary Syndrome (ACS)
2.3.1 Unstable Angina (UA)
2.3.2 Acute Myocardial Infarction (AMI)
2.3.2.1 NSTEMI/Non-Q-wave Myocardial Infarction
2.3.2.2 STEMI/Q-wave Myocardial Infarction
2.4 Most ACS Patients are UA/NSTEMI
2.5 Risk Factors

3. Treatment of Acute Coronary Syndrome
3.1 Therapeutic Categories for ACS
3.2 Antiplatelet Drugs/Platelet Aggregation Inhibitors
3.2.1 ADP Receptor Antagonists/Thienopyridines
3.2.2 Glycoprotein Inhibitors
3.2.3 COX Inhibitors and Aspirin
3.3 Anticoagulants
3.3.1 Heparins
3.3.2 Vitamin K Antagonists and Warfarin
3.4 Fibrinolytics
3.4.1 Streptokinase and Urokinase
3.4.2 Tissue Plasminogen Activators (tPA)
3.4.3 Other Fibrinolytic Agents
3.5 Anti-Ischaemic Drugs
3.5.1 Nitrates
3.5.2 Beta-Blockers
3.6 Antihypertensives
3.7 Lipid-Lowering Treatments

4. ACS Treatment Market, 2010-2021
4.1 Scope and Limitations
4.2 The World ACS Treatment Market in 2010
4.3 The Platelet Aggregation Inhibitors Drug Class Dominates the World ACS Treatment Market
4.4 Plavix: The Leading ACS Drug in 2010
4.5 The Five Leading Drugs Accounted for over 70% of the World ACS Treatment Market in 2010
4.6 The World ACS Treatment Market, 2011-2021
4.6.1 Changing Market Shares of the Leading Therapeutic Classes

5. Platelet Aggregation Inhibitors Market, 2010-2021
5.1 Platelet Aggregation Inhibitors Market, 2010
5.2 Platelet Aggregation Inhibitors Market, 2011-2021
5.3 ADP Receptor Antagonists
5.3.1 Plavix (Clopidogrel): Maintaining its Market Leading Position
5.3.1.1 Generic Competition Due to Strike in the USACS Market
5.3.1.2 Branded Competition: Marketed and in the Pipeline
5.3.1.3 Sales Forecast for Plavix in ACS, 2011-2021
5.3.2 Effient/Efient (Prasugrel), Daiichi Sankyo Company/Eli Lilly
5.3.2.1 Effient or Plavix?
5.3.2.2 Sales Forecast for Effient, 2011-2021
5.4 Glycoprotein IIb/IIIa Inhibitor
5.4.1 ReoPro (Abciximab), Eli Lilly/Centocor Ortho Biotech
5.4.1.1 Strong Competition from Integrilin
5.4.1.2 Market Presence of ReoPro Biosimilar
5.4.1.3 Sales Forecast for ReoPro, 2011-2021
5.4.2 Integrilin (Eptifibatide), Merck/GlaxoSmithKline (GSK)
5.4.2.1 Broader Indications Offering Advantage?
5.4.2.2 Sales Forecast for Integrilin, 2011-2021
5.5 COX Inhibitors
5.5.1 Aspirin Cardio, Bayer HealthCare Pharma
5.5.1.1 Aspirin Cardio Sales, 2010
5.5.1.2 Aspirin Cardio Sales Forecast, 2011-2021
5.5.1.3 OTC Treatment for the Prevention of Cardiovascular Disease?
5.6 The Future of Platelet Aggregation Inhibitors

6. Anticoagulant Treatment Market, 2010-2021
6.1 Anticoagulant Treatment Market, 2010
6.2 Anticoagulants Treatment Market, 2011-2021
6.3 Injectable Anticoagulants
6.3.1 Lovenox/Clexane (Enoxaparin), Sanofi-Aventis
6.3.1.1 Lovenox is Approved for Multiple Indications: About 10% of its 2010 Sales Were from its Use in ACS
6.3.1.2 Competition for Lovenox
6.3.1.3 Sales Forecast for Lovenox, 2011-2021
6.3.2 Angiomax/Angiox (Bivalirudin), The Medicines Company
6.3.2.1 Strong Sales Performance in EU, 2010
6.3.2.2 Sales Forecast for Angiomax, 2011-2021
6.3.3 Arixtra (Fondaparinux), GSK
6.3.3.1 Arixtra Sales for Use in ACS Patients, 2010
6.3.3.2 Generic Competition for Arixtra
6.3.3.3 Sales Forecast for Arixtra, 2011-2021
6.4 Oral Anticoagulants
6.4.1 Coumadin (Warfarin), Bristol-Myers Squibb
6.4.1.1 Competition from Generics and Pipeline Drugs
6.4.1.2 Sales Forecast for Coumadin, 2011-2021
6.5 The Future of the Anticoa

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • August 2014
  • by Global Data

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented ...

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 10 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary During the forecast period from 2012-2022, the growth of the UC market will be driven largely ...

Global Depression Therapy & Treatment Market - Depression drugs and devices, Anxiety Disorders,  SSRIs, Fischer wallace stimulator, Transcranial magnetic stimulation, Psychoanalysis, Cognitive Behavior, Psychodynamic, Electroconvulsive Pipeline Analysis,

Global Depression Therapy & Treatment Market - Depression drugs and devices, Anxiety Disorders,  SSRIs, Fischer wallace stimulator, Transcranial magnetic stimulation, Psychoanalysis, Cognitive Behavior, Psychodynamic, Electroconvulsive Pipeline Analysis,

  • $ 7 000
  • Industry report
  • November 2014
  • by Occams

Depression is a state of emotion that affects thoughts, actions and often, sleeping patterns of affected individual. Depression affects behavior in terms of loss of appetite, being in a constant state ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.